Results 51 to 60 of about 20,657 (229)
General mechanism of JQ1 in inhibiting various types of cancer
Molecular Medicine Reports, 2020 Bromodomain‑containing 4 (BRD4) is a histone modification reader and transcriptional regulator that has been reported to interact with acetylated lysine histone motifs transcription factors (TFs), transcription co‑activators and RNA polymerase II. The selective small molecule inhibitor JQ1, which binds competitively to bromodomains, has been reported ...
Jiang, Guojuan +3 more
openaire +3 more sources
Cancer Medicine, 2019 Aim JQ1, a BET bromodomain inhibitor, is a promising therapeutic approach for bladder cancer (BC). Our study aimed to determine whether autophagy is induced by JQ1 and its potential role toward proliferation in BC.
Feng Li +10 more
doaj +1 more source
Journal of Nanobiotechnology, 2022 Although combination chemoimmunotherapy shows promising clinical results for cancer treatment, this approach is largely restricted by variable objective response rate and severe systemic adverse effects of immunotherapeutic antibody and chemotherapeutic ...
Jun Gu +9 more
doaj +1 more source
BRD4 promotes heterotopic ossification through upregulation of LncRNA MANCR
Bone & Joint Research, 2021 Aims: Acquired heterotopic ossification (HO) is a debilitating disease characterized by abnormal extraskeletal bone formation within soft-tissues after injury. The exact pathogenesis of HO remains unknown.
Lei Liu +9 more
doaj +1 more source
BRD4 inhibitor JQ1 inhibits and reverses mechanical injury-induced corneal scarring [PDF]
Cell Death Discovery, 2018 AbstractCorneal scarring is characterized by the improper deposition of extracellular matrix components and myofibroblast differentiation from keratocytes. The bromodomain-containing protein 4 (BRD4) inhibitor JQ1 has been shown to attenuate pathological fibrosis.
Qu, Mingli +6 more
openaire +2 more sources
JQ1 suppresses tumor growth through downregulating LDHA in ovarian cancer*
Oncotarget, 2015 Amplification and overexpression of c-Myc is commonly seen in human ovarian cancers, and this could be a potentially novel therapeutic target for this disease. JQ1, a selective small-molecule BET bromodomain (BRDs) inhibitor, has been found to suppress tumor progression in several cancer cell types.
Haifeng, Qiu +7 more
openaire +3 more sources
Frontiers in Cellular Neuroscience, 2020 Spinal cord injury (SCI) is a destructive neurological disorder that is characterized by impaired sensory and motor function. Inhibition of bromodomain protein 4 (Brd4) has been shown to promote the maintenance of cell homeostasis by activating autophagy.
Yao Li +5 more
doaj +1 more source
Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells. role of cMYC-IRF4-miR-125b interplay [PDF]
, 2016 Background: Anticancer immune responses may contribute to the control of tumors after conventional chemotherapy and different observations have indicated that chemotherapeutic agents can induce immune responses resulting in cancer cell death and immune ...
Abruzzese, MARIA PIA +13 more
core +13 more sources
Scientific Reports, 2017 The bromodomain protein Brd4 is an epigenetic reader and plays a critical role in the development and maintenance of leukemia. Brd4 binds to acetylated histone tails and activates transcription by recruiting the positive elongation factor P-TEFb.
Tim-Michael Decker +6 more
doaj +1 more source
Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy [PDF]
, 2017 BCL-2 family proteins are central regulators of mitochondrial apoptosis and validated anti-cancer targets. Using small cell lung cancer (SCLC) as a model, we demonstrated the presence of differential addiction of cancer cells to anti-apoptotic BCL-2, BCL-
Chen, Hui-Chen +13 more
core +2 more sources